|Day Low/High||1.10 / 1.23|
|52 Wk Low/High||1.08 / 3.33|
These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.
Meaningful activity of GR-MD-02 in treating psoriasis suggests promise in treatment of non-alcoholic steatohepatitis (NASH), the company's primary target
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G.
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received a Notice of Allowance from the...
Researchers at Augusta University show galectin-3 inhibitors improve PAH in animal models
Top line results of the NASH-FX trial to be reported in September 2016
Conference Call to Begin at 8:30 a.m. ET Today
United States District Court Dismisses Both Actions With Prejudice
Forum Uniquely Brings Together Leading Family Offices, Their Foundations and Sovereign Wealth Fund Representatives Seeking Impact Investment, Grant-Giving, and Philanthropy Opportunities Within Health and Life Sciences
Providence Cancer Center Submits IND for Phase 1b Trial